Recombinant Human Granulocyte Colony-Stimulating Market Report

Europe Recombinant Human Granulocyte Colony-Stimulating Market Size, Status and Forecast 2014-2026

  • POSTDATE：Feb 20, 2020
  • PAGES：208
  • REPORT CODE：GMM478922
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Recombinant Human Granulocyte Colony-Stimulating market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.6% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Recombinant Human Granulocyte Colony-Stimulating Market Segmentations:

    By Player:

    • Gensci

    • Huaxin

    • Qilu Pharmaceutical

    • Zhaoke

    • Hangzhou Jiuyuan

    • Shijiazhuang Pharmaceutical

    • Amoytop Biotech

    • Kyowa Hakko Kirin

    • Kawin

    • Triprime

    • Amgen

    • Sinovac

    By Type:

    • Lenograstim (Granocyte)

    • Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)

    • Others

    By End-User:

    • Chemotherapy Induced Neutropenia

    • Before Blood Donation

    • Stem Cell Transplants

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Recombinant Human Granulocyte Colony-Stimulating Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Lenograstim (Granocyte) from 2014 to 2026

    • 1.3.2 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim) from 2014 to 2026

    • 1.3.3 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Chemotherapy Induced Neutropenia from 2014 to 2026

    • 1.4.2 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Before Blood Donation from 2014 to 2026

    • 1.4.3 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Stem Cell Transplants from 2014 to 2026

    • 1.4.4 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Recombinant Human Granulocyte Colony-Stimulating Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Recombinant Human Granulocyte Colony-Stimulating by Major Types

      • 3.4.1 Market Size and Growth Rate of Lenograstim (Granocyte)

      • 3.4.2 Market Size and Growth Rate of Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)

      • 3.4.3 Market Size and Growth Rate of Others

    4 Segmentation of Recombinant Human Granulocyte Colony-Stimulating Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Recombinant Human Granulocyte Colony-Stimulating by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Recombinant Human Granulocyte Colony-Stimulating for Chemotherapy Induced Neutropenia

      • 4.4.2 Market Size and Growth Rate of Recombinant Human Granulocyte Colony-Stimulating for Before Blood Donation

      • 4.4.3 Market Size and Growth Rate of Recombinant Human Granulocyte Colony-Stimulating for Stem Cell Transplants

      • 4.4.4 Market Size and Growth Rate of Recombinant Human Granulocyte Colony-Stimulating for Others

    5 Market Analysis by Major Regions

    • 5.1 Europe Recombinant Human Granulocyte Colony-Stimulating Production Analysis by Top Regions

    • 5.2 Europe Recombinant Human Granulocyte Colony-Stimulating Consumption Analysis by Top Regions

    • 5.3 Europe Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.3 France Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    6 Product Circulation of Recombinant Human Granulocyte Colony-Stimulating Market among Top Countries

    • 6.1 Top 5 Export Countries in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 7.1 Germany Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 7.2 Germany Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    8. UK Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 8.1 UK Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 8.2 UK Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    9. France Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 9.1 France Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 9.2 France Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    10. Italy Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 10.1 Italy Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 10.2 Italy Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    11. Spain Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 11.1 Spain Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 11.2 Spain Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    12. Poland Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 12.1 Poland Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 12.2 Poland Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    13. Russia Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 13.1 Russia Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 13.2 Russia Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    14. Switzerland Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 14.1 Switzerland Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 14.2 Switzerland Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    15. Turkey Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 15.1 Turkey Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 15.2 Turkey Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Top Countries

      • 16.3.1 Denmark Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

      • 16.3.2 Finland Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

      • 16.3.3 Norway Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

      • 16.3.4 Sweden Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

      • 16.3.6 Iceland Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Top Countries

      • 17.3.1 Belgium Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

      • 17.3.2 Netherlands Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

      • 17.3.3 Luxembourg Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Landscape Analysis by Top Countries

      • 18.3.1 Estonia Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

      • 18.3.2 Latvia Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

      • 18.3.3 Lithuania Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Gensci

      • 19.1.1 Gensci Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Huaxin

      • 19.2.1 Huaxin Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Qilu Pharmaceutical

      • 19.3.1 Qilu Pharmaceutical Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Zhaoke

      • 19.4.1 Zhaoke Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Hangzhou Jiuyuan

      • 19.5.1 Hangzhou Jiuyuan Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Shijiazhuang Pharmaceutical

      • 19.6.1 Shijiazhuang Pharmaceutical Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Amoytop Biotech

      • 19.7.1 Amoytop Biotech Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Kyowa Hakko Kirin

      • 19.8.1 Kyowa Hakko Kirin Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Kawin

      • 19.9.1 Kawin Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Triprime

      • 19.10.1 Triprime Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Amgen

      • 19.11.1 Amgen Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Sinovac

      • 19.12.1 Sinovac Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    The List of Tables and Figures (Totals 112 Figures and 118 Tables)

    • Figure Product Picture

    • Figure Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Lenograstim (Granocyte) from 2014 to 2026

    • Figure Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim) from 2014 to 2026

    • Figure Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Chemotherapy Induced Neutropenia from 2014 to 2026

    • Figure Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Before Blood Donation from 2014 to 2026

    • Figure Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Stem Cell Transplants from 2014 to 2026

    • Figure Europe Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure UK Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure France Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Recombinant Human Granulocyte Colony-Stimulating Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Recombinant Human Granulocyte Colony-Stimulating Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Recombinant Human Granulocyte Colony-Stimulating

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Recombinant Human Granulocyte Colony-Stimulating by Different Types from 2014 to 2026

    • Table Consumption Share of Recombinant Human Granulocyte Colony-Stimulating by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Lenograstim (Granocyte)

    • Figure Market Size and Growth Rate of Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)

    • Figure Market Size and Growth Rate of Others

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Recombinant Human Granulocyte Colony-Stimulating by Different End-Users from 2014 to 2026

    • Table Consumption Share of Recombinant Human Granulocyte Colony-Stimulating by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Chemotherapy Induced Neutropenia

    • Figure Market Size and Growth Rate of Before Blood Donation

    • Figure Market Size and Growth Rate of Stem Cell Transplants

    • Figure Market Size and Growth Rate of Others

    • Table Europe Recombinant Human Granulocyte Colony-Stimulating Production by Major Regions

    • Table Europe Recombinant Human Granulocyte Colony-Stimulating Production Share by Major Regions

    • Figure Europe Recombinant Human Granulocyte Colony-Stimulating Production Share by Major Countries and Regions in 2014

    • Table Europe Recombinant Human Granulocyte Colony-Stimulating Consumption by Major Regions

    • Table Europe Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Major Regions

    • Table Germany Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table UK Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table France Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Italy Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Spain Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Poland Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Russia Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Switzerland Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Turkey Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Recombinant Human Granulocyte Colony-Stimulating Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Germany Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Germany Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Germany Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table UK Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table UK Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table UK Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table UK Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table France Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table France Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table France Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table France Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Italy Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Italy Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Italy Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Italy Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Spain Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Spain Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Spain Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Spain Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Poland Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Poland Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Poland Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Poland Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Russia Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Russia Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Russia Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Russia Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Switzerland Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Switzerland Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Switzerland Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Turkey Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Turkey Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Turkey Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Recombinant Human Granulocyte Colony-Stimulating Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Recombinant Human Granulocyte Colony-Stimulating Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Gensci

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gensci

    • Figure Sales and Growth Rate Analysis of Gensci

    • Figure Revenue and Market Share Analysis of Gensci

    • Table Product and Service Introduction of Gensci

    • Table Company Profile and Development Status of Huaxin

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Huaxin

    • Figure Sales and Growth Rate Analysis of Huaxin

    • Figure Revenue and Market Share Analysis of Huaxin

    • Table Product and Service Introduction of Huaxin

    • Table Company Profile and Development Status of Qilu Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Qilu Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Qilu Pharmaceutical

    • Figure Revenue and Market Share Analysis of Qilu Pharmaceutical

    • Table Product and Service Introduction of Qilu Pharmaceutical

    • Table Company Profile and Development Status of Zhaoke

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Zhaoke

    • Figure Sales and Growth Rate Analysis of Zhaoke

    • Figure Revenue and Market Share Analysis of Zhaoke

    • Table Product and Service Introduction of Zhaoke

    • Table Company Profile and Development Status of Hangzhou Jiuyuan

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Hangzhou Jiuyuan

    • Figure Sales and Growth Rate Analysis of Hangzhou Jiuyuan

    • Figure Revenue and Market Share Analysis of Hangzhou Jiuyuan

    • Table Product and Service Introduction of Hangzhou Jiuyuan

    • Table Company Profile and Development Status of Shijiazhuang Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shijiazhuang Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Shijiazhuang Pharmaceutical

    • Figure Revenue and Market Share Analysis of Shijiazhuang Pharmaceutical

    • Table Product and Service Introduction of Shijiazhuang Pharmaceutical

    • Table Company Profile and Development Status of Amoytop Biotech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amoytop Biotech

    • Figure Sales and Growth Rate Analysis of Amoytop Biotech

    • Figure Revenue and Market Share Analysis of Amoytop Biotech

    • Table Product and Service Introduction of Amoytop Biotech

    • Table Company Profile and Development Status of Kyowa Hakko Kirin

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kyowa Hakko Kirin

    • Figure Sales and Growth Rate Analysis of Kyowa Hakko Kirin

    • Figure Revenue and Market Share Analysis of Kyowa Hakko Kirin

    • Table Product and Service Introduction of Kyowa Hakko Kirin

    • Table Company Profile and Development Status of Kawin

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kawin

    • Figure Sales and Growth Rate Analysis of Kawin

    • Figure Revenue and Market Share Analysis of Kawin

    • Table Product and Service Introduction of Kawin

    • Table Company Profile and Development Status of Triprime

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Triprime

    • Figure Sales and Growth Rate Analysis of Triprime

    • Figure Revenue and Market Share Analysis of Triprime

    • Table Product and Service Introduction of Triprime

    • Table Company Profile and Development Status of Amgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen

    • Figure Sales and Growth Rate Analysis of Amgen

    • Figure Revenue and Market Share Analysis of Amgen

    • Table Product and Service Introduction of Amgen

    • Table Company Profile and Development Status of Sinovac

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sinovac

    • Figure Sales and Growth Rate Analysis of Sinovac

    • Figure Revenue and Market Share Analysis of Sinovac

    • Table Product and Service Introduction of Sinovac

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US